A new Phase I/II trial has been initiated by the Multiple Myeloma Research Foundation as an exclusive signal-finding study developed to establish MM molecular drivers that will test drugs such as cobimetinib, enasidenib, abemaciclib, erdafitinib, venetoclax and daratumumab in different MM subgroups. "Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations," said Kathy Giusti, MMRF founder and co-chair at the Harvard Business School Kraft Precision Medicine Accelerator.
Platform trial launched by Multiple Myeloma Research Foundation
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.